Burning Rock Biotech (ADR)
NGS oncology testing, hospital workflows, and biopharma development services.
Something off on this page? Send us feedback.
Profile
Sells NGS-based oncology tests, hospital testing products and support, and development and testing services to pharmaceutical customers. Revenue spans a central laboratory, hospital-based testing operations, and pharma R&D services, while early-detection technology remains in clinical validation.
Combines NGS-based cancer therapy-selection and prognosis testing with minimal-residual-disease monitoring, early-detection research, and assay-development services for pharmaceutical customers. OncoScreen and OncoCompass guide treatment selection from tissue and liquid-biopsy samples; CanCatch supports recurrence monitoring. OverC, the multi-cancer early-detection program, remains in clinical validation rather than an established commercial line.
Monetizes completed tests through a central laboratory, products and workflow support through hospital laboratories, and contracted development and testing work for biopharma customers. Operations and commercial activity are centered in China, with a move toward in-hospital testing and pharma R&D services. Adoption depends on physician ordering, hospital workflow uptake, applicable diagnostic approvals, affordability, reimbursement, and pharma project timing.
Company facts
Key statistics
Year to date −48.8% · Average volume (30d) 6.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026Q1 FY26 | −$2.29 | −$0.20 | +91.3% | $19.2M | $15.7M | −18.3% | +1.83% |
| Mar 12, 2026Q4 FY25 | −$1.40 | −$0.21 | +85.0% | — | $18.1M | — | −29.93% |
| Nov 20, 2025Q3 FY25 | — | −$0.26 | — | — | $18.5M | — | −8.24% |
| Sep 8, 2025Q2 FY25 | — | −$0.15 | — | — | $20.7M | — | +4.64% |
Financial highlights
| 12 quarters | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $18.8M | $19.8M | $22.1M | $19.6M | $18.8M | $16.1M | |
| Gross profit | $13.3M | $14.5M | $16.1M | $14.7M | $14.7M | $11.6M | |
| Operating income | −$12.2M | −$2.3M | −$1.7M | −$2.4M | −$1.8M | −$2.8M | |
| Net income | −$12.1M | −$2.0M | −$1.4M | −$2.5M | −$2.3M | −$2.6M | |
| Diluted EPS | −$11.71 | −$1.86 | −$1.34 | −$2.32 | −$2.19 | −$2.53 | |
| Gross margin | 71.0% | 73.2% | 72.8% | 75.1% | 78.0% | 72.3% | |
| Operating margin | -65.0% | -11.4% | -7.7% | -12.3% | -9.5% | -17.5% |
Fiscal years (4-quarter sums)FY21 $75.6M · FY22 $83.8M · FY23 $80.0M · FY24 $76.8M · FY25 $80.3M
Revenue by product · FY25
Revenue by geography · FY24
Balance sheet, Mar 31, 2026Cash & short-term investments $66.4M · Total debt $7.6M · Total assets $117.2M · Shareholders' equity $76.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.06M · Float —
Float — provider float is below the insider stake.
Insiders — filings are in another share unit.
The Form 4 positions here total more than the shares outstanding, so the filings and the share count are not on the same basis — usually an unlisted unit behind the listed one — and no insider percentage is shown.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| CRCM LP | 282.1K | 26.69% | 13F | May 13, 2026 |
| Renaissance Technologies LLC | 35.4K | 3.35% | 13F | May 14, 2026 |
| Nikko Asset Management Americas, Inc. | 30.1K | 2.85% | 13F | May 7, 2026 |
| Sumitomo Mitsui Trust Group, Inc. | 30.1K | 2.85% | 13F | Apr 30, 2026 |
| Bank of America Corp /DE/ | 29.2K | 2.76% | 13F | May 18, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | Yusheng Han | director | +24,760 | $8.74 |
| Jun 12, 2026 | Yusheng Han | director | +210,000 | $9.25 |
| Jun 16, 2026 | Yusheng Han | director | +111,110 | $9.00 |
| Jun 22, 2026 | Yusheng Han | director | +104,650 | $7.45 |
| Jun 23, 2026 | Yusheng Han | director | +5,990 | $7.50 |
Peers
- Guardant Health
Liquid-biopsy profiling and companion diagnostics for advanced cancer.
- Caris Life Sciences
Broad tissue and blood molecular profiling, MRD, and early detection.
- Tempus AI
Oncology genomic diagnostics combined with hospital and pharma data tools.
- NeoGenomics
Oncology reference-lab testing with molecular profiling and pharma services.
- Natera
Tumor-informed ctDNA monitoring for MRD and cancer recurrence.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Burning Rock Biotech (ADR) | $10.08 | 0.00% | $10.8M | — | — | 0.1 | −14.2% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Median | 71.6 | 83.3 | 7.8 | +37.7% |